Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Transgenomic to work with NCI on mitochondrial gene project
June 2008
SHARING OPTIONS:

OMAHA, Neb.Transgenomic Inc., a global genetic analysis and services company, recently announced that the National Cancer Institute (NCI) has approved a proposal to perform mutational analysis and sequencing of the mitochondrial genes in the NCI 60 cancer cell line panel. Mitochondrial damage is increasingly recognized as an early warning signal in several different types of cancer. This is the first comprehensive evaluation of the mitochondrial genome in the NCI 60 panel.

"Tens of thousands of compounds have been tested against the NCI 60 cell lines in the NCI's pharmacological database of cancer drugs," says Dr. Eric Kaldjian, CSO of Transgenomic. "This collaboration makes it possible to test whether in vitro responses to anti-cancer agents are linked to alterations in the mitochondrial genome and can be detected with our sensitive mutation detection technology."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.